NūGensia™ (Akkermansia muciniphila Postbiotic)

Akkermansia muciniphila
Evidence Level
Moderate
2 Clinical Trials
3 Documented Benefits
3/5 Evidence Score

NūGensia™ is a branded Akkermansia muciniphila (strain VHAKM) postbiotic from Vidya Herbs, starch-shell encapsulated and dosed at about 10 billion CFU/day, marketed for blood-sugar, weight and metabolic support. The Akkermansia class is backed by landmark human trials — including a Nature Medicine proof-of-concept RCT showing improved metabolic markers in overweight adults. Honest framing: NūGensia's own branded trial is in a non-PubMed-indexed journal, so it leans on the strong generic Akkermansia evidence. See the generic Akkermansia muciniphila entry.

Studied Dose Manufacturer trial: ~10 billion CFU/day for 60 days. The landmark Akkermansia RCT used ~10 billion cells/day (live or pasteurized).
Active Compound Akkermansia muciniphila (strain VHAKM), starch-shell encapsulated, ~10 billion CFU/day. NūGensia™ is manufactured by Vidya Herbs.

Benefits

Improved glucose and metabolic markers

Akkermansia muciniphila supplementation improved insulin sensitivity and metabolic markers in a Nature Medicine RCT; NūGensia's manufacturer trial in prediabetic adults reports lower fasting and post-meal glucose and HbA1c. Strong class evidence.

Weight and waist support

The Akkermansia trials reported modest reductions in body weight, fat mass and waist circumference, consistent with NūGensia's positioning.

Gut-barrier support

Akkermansia is a mucin-associated commensal that strengthens the gut barrier, a mechanism linking it to metabolic health.

Mechanism of action

1

Gut-barrier and mucin layer support

Akkermansia muciniphila lives in and reinforces the intestinal mucus layer, reducing 'leaky gut' and the low-grade inflammation that drives metabolic dysfunction.

2

Metabolic endotoxemia reduction

By tightening the gut barrier, Akkermansia lowers circulating bacterial endotoxin, improving insulin sensitivity and metabolic markers.

Clinical trials

1
Akkermansia muciniphila Metabolic RCTs (class)

Depommier 2019 proof-of-concept RCT (Nature Medicine) and a 2026 Nature Medicine weight-loss study.

Overweight/obese adults with metabolic risk

Supplementation (live or pasteurized) improved insulin sensitivity and metabolic markers and supported weight loss versus placebo — landmark evidence for the class.

2
Branded NūGensia Trial (manufacturer)

Randomized, placebo-controlled, n=60 prediabetic adults, ~10 billion CFU/day for 60 days. Published in a non-PubMed-indexed journal.

Adults with prediabetes (31–60 y)

Manufacturer reports lower fasting/postprandial glucose, HbA1c and triglycerides, with reduced weight/BMI/waist. Treat as manufacturer evidence supported by the class data.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated; Akkermansia is a normal human gut commensal.
Mild, transient bloating or changes in bowel habit possible when starting.
Immunocompromised individuals should use live/postbiotic bacteria under clinician guidance.
Long-term data are still accumulating for this relatively new probiotic.

Important Drug interactions

No well-documented drug interactions.
Antidiabetic medications: monitor glucose, as additive effects are plausible given the metabolic action.

Frequently asked questions about NūGensia™ (Akkermansia muciniphila Postbiotic)

What is NūGensia?

NūGensia is Vidya Herbs' branded Akkermansia muciniphila postbiotic, encapsulated for stability and dosed around 10 billion CFU/day for blood-sugar, weight and metabolic support. Akkermansia is one of the most promising next-generation metabolic probiotics.

Is Akkermansia actually proven?

The class has landmark human evidence, including a Nature Medicine proof-of-concept RCT showing improved metabolic markers in overweight adults. NūGensia's own trial is manufacturer-run and not PubMed-indexed, so it leans on that strong generic Akkermansia evidence.

What is NūGensia used for?

NūGensia is researched primarily for Metabolic Health, Gut Health, and Weight Management. Akkermansia muciniphila supplementation improved insulin sensitivity and metabolic markers in a Nature Medicine RCT; NūGensia's manufacturer trial in prediabetic adults reports lower fasting and post-meal glucose and HbA1c.

What is the recommended dosage of NūGensia?

The clinically studied dose is Manufacturer trial: ~10 billion CFU/day for 60 days. The landmark Akkermansia RCT used ~10 billion cells/day (live or pasteurized). Always follow the product label and check with a healthcare provider for personal advice.

Is NūGensia safe, and does it have side effects?

For most healthy adults, NūGensia is well tolerated at studied doses. Reported effects can include: Generally well tolerated; Akkermansia is a normal human gut commensal. Mild, transient bloating or changes in bowel habit possible when starting. It may also interact with some medications. NūGensia is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does NūGensia interact with any medications?

Possible interactions include: No well-documented drug interactions. Antidiabetic medications: monitor glucose, as additive effects are plausible given the metabolic action. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for NūGensia?

NutraSmarts rates the evidence for NūGensia as Moderate (3 out of 5). It is backed by 2 clinical trials and 2 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Mount S, Canfora EE, Jocken JW, Umanets A, Hul G, Coenjaerds M, et al. Pasteurized Akkermansia muciniphila Muc(T) for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nature Medicine. 2026;. doi: 10.1038/s41591-026-04394-7.PubMedUsed to support: A 2026 Nature Medicine study of pasteurized Akkermansia muciniphila for weight loss — landmark evidence for the Akkermansia probiotic class behind NuGensia.
  2. Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. 2019;25(7):1096-1103. doi: 10.1038/s41591-019-0495-2.PubMedUsed to support: The pivotal Depommier 2019 Nature Medicine proof-of-concept RCT: supplementation with Akkermansia muciniphila in overweight/obese adults improved metabolic markers — the foundational human evidence for the Akkermansia class behind NuGensia.